JP2020502262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502262A5 JP2020502262A5 JP2019547602A JP2019547602A JP2020502262A5 JP 2020502262 A5 JP2020502262 A5 JP 2020502262A5 JP 2019547602 A JP2019547602 A JP 2019547602A JP 2019547602 A JP2019547602 A JP 2019547602A JP 2020502262 A5 JP2020502262 A5 JP 2020502262A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- tumor cell
- seq
- cell line
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 210000004881 tumor cell Anatomy 0.000 claims 15
- 108010029697 CD40 Ligand Proteins 0.000 claims 10
- 230000002519 immonomodulatory effect Effects 0.000 claims 9
- 239000012528 membrane Substances 0.000 claims 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 8
- 102100032937 CD40 ligand Human genes 0.000 claims 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 7
- 229940030664 allogeneic tumor cell vaccine Drugs 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 229940068196 placebo Drugs 0.000 claims 2
- 239000000902 placebo Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108700012920 TNF Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005016 dendritic process Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023006527A JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425424P | 2016-11-22 | 2016-11-22 | |
| US62/425,424 | 2016-11-22 | ||
| PCT/US2017/063016 WO2018098279A1 (en) | 2016-11-22 | 2017-11-22 | Allogenic tumor cell vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006527A Division JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502262A JP2020502262A (ja) | 2020-01-23 |
| JP2020502262A5 true JP2020502262A5 (https=) | 2021-01-14 |
| JP7629178B2 JP7629178B2 (ja) | 2025-02-13 |
Family
ID=62195656
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547602A Active JP7629178B2 (ja) | 2016-11-22 | 2017-11-22 | 同種異系腫瘍細胞ワクチン |
| JP2023006527A Pending JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006527A Pending JP2023055758A (ja) | 2016-11-22 | 2023-01-19 | 同種異系腫瘍細胞ワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11058752B2 (https=) |
| EP (1) | EP3545001A4 (https=) |
| JP (2) | JP7629178B2 (https=) |
| KR (2) | KR20240024328A (https=) |
| AU (1) | AU2017363256B2 (https=) |
| WO (1) | WO2018098279A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12516292B2 (en) * | 2016-07-25 | 2026-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| JP7086928B2 (ja) | 2016-07-25 | 2022-06-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| KR20240024328A (ko) | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| US11185586B2 (en) | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
| US10731128B2 (en) | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| EP3810641A4 (en) * | 2018-06-19 | 2022-07-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | ONCOLYTIC VIRUS OR ANTIGEN PRESENT CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40 LIGAND |
| KR20210093977A (ko) * | 2018-11-19 | 2021-07-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 자살 유전자 |
| SG11202111865UA (en) | 2019-05-01 | 2021-11-29 | Pact Pharma Inc | Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy |
| US20220211832A1 (en) * | 2019-05-15 | 2022-07-07 | Genocea Biosciences, Inc. | Treatment methods |
| CA3142023A1 (en) * | 2019-05-28 | 2020-12-03 | Case Western Reserve University | Compositions and methods for preserving dna methylation |
| WO2020254591A1 (en) * | 2019-06-19 | 2020-12-24 | Julius-Maximilians-Universität Würzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| IL292355A (en) * | 2019-10-22 | 2022-06-01 | Alloplex Biotherapeutics | Compositions and methods for in vitro activation and expansion of serial killer t-cell populations and passive vaccination of a cancer patient with tumor cell-killing cells |
| TW202134430A (zh) | 2019-12-03 | 2021-09-16 | 美商紐沃進公司 | 腫瘤細胞疫苗 |
| EP4164750A4 (en) * | 2020-06-11 | 2024-04-17 | Alloplex Biotherapeutics | Allogeneic tumor cell vaccine |
| US20230257703A1 (en) * | 2020-06-19 | 2023-08-17 | Iowa State University Research Foundation, Inc. | Nanoscale polymeric micellar scaffolds for rapid and efficient antibody production |
| EP4526457A2 (en) * | 2022-06-30 | 2025-03-26 | Meridian Therapeutics, Inc. | A vaccine composition of cells expressing a lentiviral vector and methods of using |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882654A (en) | 1989-11-03 | 1999-03-16 | Morton; Donald L. | Polyvalent melanoma vaccine |
| AU677165B2 (en) | 1991-10-04 | 1997-04-17 | Johns Hopkins University School Of Medicine, The | The regulation of systemic immune responses utilizing cytokines and antigens |
| ATE283069T1 (de) | 1996-08-16 | 2004-12-15 | Univ Johns Hopkins Med | Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung |
| US6682928B2 (en) * | 1997-12-02 | 2004-01-27 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
| WO2001009303A2 (en) * | 1999-07-30 | 2001-02-08 | Vical Inc. | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
| AU2001231204A1 (en) | 2000-01-27 | 2001-08-07 | Sidney Kimmel Cancer Center | Genetically engineered tumor cell vaccines |
| US7087225B2 (en) | 2001-08-16 | 2006-08-08 | Human Genome Sciences, Inc. | Methods and compositions for treating metabolic bone diseases relating to human endokine alpha |
| WO2003045428A2 (de) | 2001-11-30 | 2003-06-05 | Medigene Aktiengesellschaft | Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung |
| US20070243159A1 (en) | 2003-04-30 | 2007-10-18 | Periasamy Selvaraj | Therapeutic Compositions and Vaccines By Glycosyl-Phosphatidylinositol (Gpi)-Anchored Cytokines and Immunostimulatory Molecules |
| CA2540283C (en) * | 2003-09-26 | 2019-05-21 | University Of Miami | Tumor vaccine |
| PL1699480T3 (pl) * | 2003-12-30 | 2011-11-30 | Mologen Ag | Allogeniczny przeciwnowotworowy czynnik terapeutyczny |
| WO2007143681A2 (en) | 2006-06-06 | 2007-12-13 | University Of Rochester | Helper virus-free herpesvirus amplicon particles and uses thereof |
| US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
| MX2009006277A (es) | 2006-12-14 | 2009-07-24 | Medarex Inc | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. |
| WO2009095033A1 (en) | 2008-01-31 | 2009-08-06 | Agirx Limited | Vaccine compositons |
| WO2011004201A1 (en) | 2009-07-10 | 2011-01-13 | Mark Lowdell | Preserved compositions of activated nk cells and methods of using the same |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2016168197A1 (en) | 2015-04-15 | 2016-10-20 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
| US20180267024A1 (en) | 2015-06-08 | 2018-09-20 | Lophius Biosciences Gmbh | Composition for determination of cell-mediated immune responsiveness |
| WO2017133175A1 (en) | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| KR20240024328A (ko) * | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| US11185586B2 (en) * | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| CN111133109A (zh) * | 2017-06-13 | 2020-05-08 | 昂科赛克医疗公司 | 用于免疫调节蛋白表达的多基因构建体和其使用方法 |
| CN113194945B (zh) * | 2018-08-23 | 2024-07-23 | 佩勒梅德有限公司 | 环吡酮的抑制hbv核心组装的用途 |
| JP7178139B2 (ja) * | 2018-12-11 | 2022-11-25 | オンコセック メディカル インコーポレイテッド | 免疫調節タンパク質発現のための多重遺伝子構築物および使用方法 |
| EP4164750A4 (en) * | 2020-06-11 | 2024-04-17 | Alloplex Biotherapeutics | Allogeneic tumor cell vaccine |
-
2017
- 2017-11-22 KR KR1020247004557A patent/KR20240024328A/ko active Pending
- 2017-11-22 EP EP17873638.5A patent/EP3545001A4/en active Pending
- 2017-11-22 KR KR1020197018010A patent/KR20190100200A/ko not_active Ceased
- 2017-11-22 AU AU2017363256A patent/AU2017363256B2/en active Active
- 2017-11-22 US US15/821,105 patent/US11058752B2/en active Active
- 2017-11-22 JP JP2019547602A patent/JP7629178B2/ja active Active
- 2017-11-22 WO PCT/US2017/063016 patent/WO2018098279A1/en not_active Ceased
-
2021
- 2021-04-16 US US17/233,124 patent/US12403186B2/en active Active
-
2023
- 2023-01-19 JP JP2023006527A patent/JP2023055758A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502262A5 (https=) | ||
| US11732017B2 (en) | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use | |
| Tay et al. | CD40L expression allows CD8+ T cells to promote their own expansion and differentiation through dendritic cells | |
| JP7122336B2 (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| JP2022531231A5 (https=) | ||
| CN104087592B (zh) | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 | |
| MX2022012409A (es) | Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores. | |
| Deauvieau et al. | Human natural killer cells promote cross‐presentation of tumor cell‐derived antigens by dendritic cells | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2004537252A5 (https=) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2017530114A (ja) | フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物 | |
| JP6697076B2 (ja) | ウイルス抗原特異的ｔ細胞の濃縮および拡大方法 | |
| CN101824400A (zh) | 一种放大增殖抗原特异性t细胞的方法 | |
| Tomita et al. | Identification of CDCA1‐derived long peptides bearing both CD4+ and CD8+ T‐cell epitopes: CDCA1‐specific CD4+ T‐cell immunity in cancer patients | |
| Zhang et al. | Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| JP2014519311A5 (https=) | ||
| CN102898528B (zh) | 钙网蛋白-可溶性程序性死亡受体1的融合蛋白及其制备方法和用途 | |
| Dorn et al. | Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope | |
| NZ789406A (en) | Engineered immune killer cell, preparation method therefor and use thereof | |
| Ni et al. | Antitumor vaccination by Newcastle Disease Virus Hemagglutinin–Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity | |
| CN110234657B (zh) | 用于激活cd40和sting通路的表达基因佐剂的病毒载体构建体 | |
| Zong et al. | Identification of Co-inhibitory receptors PD-1 and TIM-3 on t cells from gastric cancer patients | |
| CN104761636B (zh) | 一种HLA-A33限制性eEF2表位多肽及其应用 |